The synthetic retinoic acid, 13-cis-retinoic acid, is an established component of the treatment given to children with high-risk NB to reduce minimal residual disease[16,17] and exposure of a number of NB cell lines, such as SK-N-BE, to ATRA induces neural cell differentiation along with down-regulation of MYCN[18]. Here, MYCN is linked to neuroblastoma.